Search results
Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS
Key Points
- Interested in Clene Inc.? Here are five stocks we like better.
- Clene plans to file an NDA for CNM-Au8 in early Q4 as a potential ALS treatment after five FDA meetings. The agency
Clene Inc. (CLNN) Reports Q2 Loss, Beats Revenue Estimates
Clene Inc. (CLNN) came out with a quarterly loss of $0.6 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.78 per share a year ago. These figures are


